BACKGROUND INFORMATION ON THE PROCEDURE 
1.  
Submission of the dossier 
The  applicant  Novartis  Europharm  Ltd.  submitted  on  9  August  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Dafiro,  through  the  centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 14 December 2005.  
The legal basis for this application refers to:  
Article 10(b) of Directive 2001/83/EC, as amended – relating to applications new fixed combination 
products. 
The  application  submitted  is  a  complete  dossier:  composed  of  administrative  information,  complete 
quality  data,  non-clinical  and  clinical  data  based  on  applicants’  own  tests  and  studies  and/or 
bibliographic literature substituting/supporting certain test(s) or studies. 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  
Steffen Thirstrup 
Co-Rapporteur: Alar Irs 
2.  
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 9 August 2006. 
The procedure started on 20 August 2006. 
This  application  forms  part  of  a  multiple  application  for  amlodipin/valsartan.  The  initial 
application was submitted by Novartis Europharm Ltd. (EMEA/H/C/716). The review process 
for both applications has been integrated at the time of the Responses to the List of Questions, 
allowing the CHMP opinion to be adopted in the same timeframe as EMEA/H/C/716.  
The applicant submitted the responses to the CHMP consolidated List of Questions on 9 August 
2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 26 September 2006. 
During  the  CHMP  meeting  on  16  –  18  October  2006,  the  CHMP  agreed  on  a  List  of 
Outstanding Issues to be addressed in writing by the. 
 The applicant submitted the responses to the CHMP consolidated List of Outstanding Issues on 
24 October 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 1 November 2006. 
During  the  meeting  on  13  –  16  November  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Dafiro on 16 November 2006. The applicant provided the 
letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 24 October 
2006.  
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 16 January 2007. 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
